Literature DB >> 22118826

Rates and implications for hospitalization of patients ≥65 years of age with atrial fibrillation/flutter.

Gerald V Naccarelli1, Stephen S Johnston, Mehul Dalal, Jay Lin, Parag P Patel.   

Abstract

The responsibility of managing atrial fibrillation (AF) and atrial flutter (AFL) falls predominantly on the Medicare system. Patients with AF or AFL often have a range of cardiovascular (CV) co-morbidities and are frequently hospitalized for AF and other CV causes. The present retrospective cohort study used medical claims data to evaluate the rates of hospitalization and inpatient mortality in elderly (aged ≥65 years) patients with AF or AFL with Medicare supplemental insurance. The data were extracted from the United States Thomson Reuters MarketScan Medicare Supplemental and Coordination of Benefits Database (January 2004 to December 2007). Patients aged ≥65 years with ≥1 inpatient or ≥2 outpatient nondiagnostic claims for AF or AFL and ≥12 months of continuous enrollment before their index AF or AFL diagnoses were identified. The frequencies of hospitalization and inpatient death were evaluated over the postindex study period (mean 24.3 months). Of an eligible study population of 55,774 patients with AF or AFL (mean age 77.9 years, 52.2% men), 28,939 patients (51.9%) were hospitalized (all causes) with nonfatal outcomes, 12,652 (22.7%) were rehospitalized, and 1,592 (2.9%) died in the hospital. Higher proportions of patients were hospitalized for non-CV than for CV causes (35.6% vs 27.2%). For CV hospitalizations culminating in inpatient death (n = 516), the most common admission diagnoses were major bleeding, stroke or transient ischemic attack, and congestive heart failure. In conclusion, elderly patients with AF or AFL undergo frequent hospitalization for CV and non-CV causes. Measures that lower inpatient admission rates, particularly readmission rates, may reduce the increasing cost of treating patients with AF or AFL with Medicare supplemental insurance.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22118826     DOI: 10.1016/j.amjcard.2011.10.009

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  19 in total

Review 1.  Arterial Hypertension, Atrial Fibrillation, and Hyperaldosteronism: The Triple Trouble.

Authors:  Teresa M Seccia; Brasilina Caroccia; Gail K Adler; Giuseppe Maiolino; Maurizio Cesari; Gian Paolo Rossi
Journal:  Hypertension       Date:  2017-04       Impact factor: 10.190

2.  Adherence to guideline recommendations for antiarrhythmic drugs in atrial fibrillation.

Authors:  Nancy M Allen LaPointe; Yuliya Lokhnygina; Gillian D Sanders; Eric D Peterson; Sana M Al-Khatib
Journal:  Am Heart J       Date:  2013-09-24       Impact factor: 4.749

3.  Perceived Stress and Atrial Fibrillation: The REasons for Geographic and Racial Differences in Stroke Study.

Authors:  Wesley T O'Neal; Waqas Qureshi; Suzanne E Judd; Stephen P Glasser; Lama Ghazi; LeaVonne Pulley; Virginia J Howard; George Howard; Elsayed Z Soliman
Journal:  Ann Behav Med       Date:  2015-12

4.  Drivers of hospitalization for patients with atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF).

Authors:  Benjamin A Steinberg; Sunghee Kim; Gregg C Fonarow; Laine Thomas; Jack Ansell; Peter R Kowey; Kenneth W Mahaffey; Bernard J Gersh; Elaine Hylek; Gerald Naccarelli; Alan S Go; James Reiffel; Paul Chang; Eric D Peterson; Jonathan P Piccini
Journal:  Am Heart J       Date:  2014-02-17       Impact factor: 4.749

5.  Comparisons of hospitalization rates among younger atrial fibrillation patients receiving different antiarrhythmic drugs.

Authors:  Nancy M Allen LaPointe; David Dai; Laine Thomas; Jonathan P Piccini; Eric D Peterson; Sana M Al-Khatib
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2015-03-31

Review 6.  Care transitions in anticoagulation management for patients with atrial fibrillation: an emphasis on safety.

Authors:  Steven Deitelzweig
Journal:  Ochsner J       Date:  2013

7.  Antiarrhythmic drug use in patients <65 years with atrial fibrillation and without structural heart disease.

Authors:  Nancy M Allen LaPointe; Dadi Dai; Laine Thomas; Jonathan P Piccini; Eric D Peterson; Sana M Al-Khatib
Journal:  Am J Cardiol       Date:  2014-11-13       Impact factor: 2.778

8.  Fall Risk and Outcomes Among Patients Hospitalized With Cardiovascular Disease in the Community.

Authors:  Sheila M Manemann; Alanna M Chamberlain; Cynthia M Boyd; Donna M Miller; Kimberly L Poe; Andrea Cheville; Susan A Weston; Ellen E Koepsell; Ruoxiang Jiang; Véronique L Roger
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2018-08

9.  Intracranial hemorrhage mortality in atrial fibrillation patients treated with dabigatran or warfarin.

Authors:  Alvaro Alonso; Lindsay G S Bengtson; Richard F MacLehose; Pamela L Lutsey; Lin Y Chen; Kamakshi Lakshminarayan
Journal:  Stroke       Date:  2014-07-03       Impact factor: 7.914

10.  Use Of Rate And Rhythm Control Drugs In Patients Younger Than 65 Years With Atrial Fibrillation.

Authors:  Nancy M Allen LaPointe; Yuliya Lokhnygina; Jacqueline Rimmler; Gillian D Sanders; Eric D Peterson; Sana M Al-Khatib
Journal:  J Atr Fibrillation       Date:  2014-06-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.